Trials / Completed
CompletedNCT04472650
Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Adults
A Phase 1, Open-label, Single-dose, Randomized Crossover Study to Evaluate the Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- BeiGene · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of the study was to investigate the relative bioavailability and pharmacokinetics (PK) of sitravatinib free base and malate salt capsule formulations following oral administration in healthy adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sitravatinib | Administered orally as a free base capsule |
| DRUG | Sitravatinib | Administered orally as a malate salt capsule |
Timeline
- Start date
- 2020-07-23
- Primary completion
- 2020-11-09
- Completion
- 2020-11-09
- First posted
- 2020-07-15
- Last updated
- 2024-10-26
- Results posted
- 2021-12-27
Locations
1 site across 1 country: Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04472650. Inclusion in this directory is not an endorsement.